Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
Savara Management to Meet Virtually With Piper Sandler
Evercore Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $7
Evercore ISI Remains a Buy on Savara (SVRA)
Savara Announces Patient Journey Map for People Living With Autoimmune Pulmonary Alveolar Proteinosis (APAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
Savara Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Savara Analyst Ratings
Savara's Molbreevi: A $400 Million Opportunity Backed by Promising Clinical Data and Market Expansion Initiatives
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $15
JMP Securities Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9
Buy Rating Affirmed for Savara on Strong Prospects for Molgramostim in APAP Treatment
Savara Announces New Employment Inducement Grant
Savara Initiates Early Access Program for Rare Lung Disease Treatment
Savara Announces EAP for Molgramostim for Patients With APAP
Express News | Savara Inc: Plans to Complete Submission of a Bla to FDA for Molgramostim in Apap in H1 of 2025
Express News | Savara : Savara Early Access Accepting Requests From Patients in Select Countries in N.america & Europe, Plans to Expand Through 2026
Express News | Savara Announces Expanded Access Program (Eap) for Molgramostim Inhalation Solution (Molgramostim) for Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap)
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients With Autoimmune Pulmonary Alveolar Proteinosis (APAP)
Savara: Parker Has Over 25 Years of Comml Leadership Experience >SVRA